Breast carcinoma by gene expression profile

This phase 1 trial tests an investigational DNA vaccine called pING-hHER3FL in people whose solid tumors have been surgically removed. The vaccine carries the genetic code for the HER3 protein, which is found on many cancer types, and aims to trigger a targeted immune response ag…

This early-phase study tests a new drug called inavolisib in people with advanced solid tumors or breast cancer that have a specific PIK3CA gene mutation. The study aims to find a safe dose and see how well the drug works alone or with other cancer treatments. About 200 participa…

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This phase 3 trial tests a new drug called SHR-A1811, given alone or with pertuzumab, against the standard treatment (trastuzumab, pertuzumab, and docetaxel) in 868 women with HER2-positive breast cancer that has returned or spread. The goal is to see if the new approach can dela…

This early-phase trial is testing whether adding a drug called copanlisib to the standard two-drug therapy (fulvestrant and abemaciclib) can better control hormone receptor-positive, HER2-negative metastatic breast cancer that has stopped responding to hormone therapy. The study …

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This large phase 3 trial studied over 10,000 women with early-stage, hormone-receptor-positive breast cancer that hasn't spread to lymph nodes. It used the Oncotype DX test to assign women to hormone therapy alone or hormone therapy plus chemotherapy based on their recurrence sco…

This phase III trial tests whether a smartphone app called Quit2Heal can help cancer patients stop smoking better than the standard QuitGuide app. The study involves 427 adults with cancer who smoke and are interested in quitting. Participants use one of the two apps to get suppo…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …

This early-stage trial tests a new approach for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. It combines a radioactive drug (lutetium NeoB) that targets cancer cells with a standard chemotherapy pill (capecitabi…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This study tests a system called CONCURxP that uses a smart pill dispenser (WiseBag) and text message reminders to help people with metastatic breast cancer take their CDK4/6 inhibitor pills as prescribed. About 410 patients will be split into two groups: one gets the full system…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…

This Phase 3 trial is testing whether adding the immunotherapy drug atezolizumab to the targeted therapy trastuzumab emtansine (Kadcyla) can prevent breast cancer from returning in people with high-risk HER2-positive breast cancer. About 1,188 participants who still had cancer af…

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This phase 3 trial tests whether adding the drug palbociclib to standard hormone therapy can help prevent breast cancer from coming back in people with a specific type of breast cancer (HR+/HER2-). About 405 participants who had surgery for a local or regional recurrence will rec…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This early-phase trial is testing a gel form of the drug endoxifen, applied to the skin, in 32 women scheduled for breast surgery. The goal is to see if the gel is safe and how much of the drug gets into breast tissue and blood. If successful, it might offer a gentler way to trea…

This Phase 3 trial tests whether giving one type of chemotherapy before another, before surgery, changes the chances of staying cancer-free in people with locally advanced HER2-negative breast cancer. Participants receive either a taxane (docetaxel or paclitaxel) first, followed …

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This study tests a new oral drug, vepdegestrant, combined with abemaciclib in people with advanced or metastatic ER+ breast cancer that no longer responds to prior treatments. About 37 adults will take both pills daily at home, with clinic visits every 4 weeks, to see if the comb…

This phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This phase III trial compares low-dose tamoxifen to standard hormone therapy (aromatase inhibitors) in postmenopausal women with low-risk, hormone-positive, HER2-negative early breast cancer. The goal is to see if the lower dose works just as well to prevent cancer from coming ba…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …

This study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it hel…

This study looks at the long-term safety of a drug called TOL2506, which suppresses ovarian function, in people with hormone receptor-positive (HR+) breast cancer. It includes premenopausal women and men who already completed a previous study. Participants will take TOL2506 along…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells by attaching to them and blocking growth. About 11…

This study tests a clinic program called ActivityChoice that helps cancer survivors become more physically active to lower their risk of heart disease. About 114 adult cancer survivors will be offered a choice of group in-person, group virtual, or self-monitored digital exercise …

This phase 1 trial tests whether a personalized aerobic exercise program, including supervised walking sessions done remotely, can be safely added to the usual first-line hormone therapy for metastatic breast cancer. Researchers want to see if exercise helps delay the development…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This phase III trial tests whether adding pembrolizumab (Keytruda) after standard chemotherapy can help prevent triple-negative breast cancer from coming back. Over 1,100 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or placebo. The stud…

This study tests whether certain women with early-stage HER2-positive breast cancer can be treated with a targeted drug combination (PHESGO™) without chemotherapy. Researchers use specific markers to select patients whose tumors are highly dependent on the HER2 pathway. The goal …

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This study tests whether adding belzutifan to fulvestrant can slow or stop the growth of a certain type of advanced breast cancer (ER+/HER2-) that has worsened despite hormone therapy. About 120 adults with inoperable or metastatic disease will receive either the new combination …

This early-phase trial is testing whether giving two drugs—lenvatinib and pembrolizumab—before surgery can boost the immune response in people with early-stage triple-negative breast cancer. Only 12 participants will receive the short treatment before their planned surgery. The m…

This phase II trial tests whether adding an immunotherapy drug (atezolizumab) to a targeted therapy (olaparib) works better than olaparib alone for advanced non-HER2-positive breast cancer that has a BRCA mutation. About 81 patients with locally advanced or metastatic disease are…

This study tests whether a newer drug, Z-Endoxifen, works better than the standard tamoxifen for postmenopausal women with advanced ER+/HER2- breast cancer. About 81 participants will receive one of the two hormone therapies to see which delays cancer growth longer. The goal is t…

This early-stage trial tests an oral drug called RGT-419B in Chinese patients with advanced or metastatic breast cancer that is hormone receptor positive and HER2 negative, as well as other advanced solid tumors. The main goal is to see if the drug is safe and tolerable, and to f…

This early-stage study tests a new drug (H3B-6545) combined with an existing drug (palbociclib) in women with advanced or metastatic ER+ HER2- breast cancer. The main goal is to find the safest dose and understand side effects. About 31 women who have already tried other treatmen…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …

This study tested a new oral drug, AZD9833, against a standard injected treatment (fulvestrant) in 240 women with advanced ER-positive, HER2-negative breast cancer. The main goal was to see how long the cancer stayed under control. Results from one dose group were limited because…

This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…

This early-stage trial tests a new drug called runimotamab, alone or with trastuzumab, in 123 people with advanced HER2-positive cancers. The main goal is to check safety and how the drug moves through the body. It is for patients whose cancer has spread or cannot be removed by s…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-phase trial tested a drug called Z-endoxifen in 62 people with a type of breast cancer that has spread or come back. The goal was to find the safest dose and check for side effects. Z-endoxifen works by blocking estrogen, which some breast cancers need to grow.

This early-stage trial is testing an experimental drug called IBI363 in people with advanced solid tumors or lymphoma that have progressed despite standard treatment. IBI363 is designed to boost the immune system in two ways: by stimulating immune cells with an IL-2-like signal a…

This Phase 3 trial is testing an experimental drug called Dato-DXd against standard chemotherapy in 732 people with advanced HR-positive, HER2-negative breast cancer. Participants have already tried one or two prior chemotherapies. The study aims to see if Dato-DXd can slow cance…

This early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to standard treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it …

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This phase 3 study tests whether adding alpelisib (a targeted pill) to fulvestrant (a hormone-blocking shot) can slow cancer growth in men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. Participants must have already tr…

This early-stage study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants will take pa…

This phase II trial is testing a combination of four drugs—trilaciclib, pembrolizumab, gemcitabine, and carboplatin—in people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. The study aims to see how well the treatment works and how sa…

This study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…

This trial is testing whether combining the targeted drug trastuzumab with either oral chemotherapy or hormone therapy can effectively treat stage I HER2-positive breast cancer. The study includes women aged 18-70 with small, lymph-node-negative tumors, divided into two groups ba…

This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This early-phase trial tests a new drug called AZD9833, alone or with other medicines, in women with a specific type of advanced breast cancer (ER-positive, HER2-negative). The main goals are to check safety and find the right dose. About 396 women will take part. This is not a c…

This trial is testing whether combining chemotherapy with two immunotherapy drugs, given before surgery, can completely eliminate triple-negative breast cancer in people with stage II-III disease. Participants will receive six cycles of the combination, and the main goal is to se…

This phase 3 trial tests whether adding the targeted drug ribociclib to standard hormone therapy can help prevent breast cancer from coming back in people with early-stage, hormone receptor-positive, HER2-negative breast cancer. Over 5,000 participants are randomly assigned to re…

This phase III trial is testing whether the drug pyrotinib can further reduce the risk of breast cancer returning in women with HER2-positive early or locally advanced breast cancer who have already completed standard treatment with trastuzumab. Participants will be randomly assi…

This phase 3 trial is testing a combination of two drugs—capivasertib (a pill that targets cancer cell growth) and fulvestrant (an injection that blocks estrogen)—in 258 Chinese patients with advanced HR+/HER2- breast cancer that has worsened after hormone therapy. The study focu…

This study tests whether adding the experimental drug capivasertib to standard hormone therapy and CDK4/6 inhibitors can delay cancer growth in people with advanced HR+/HER2- breast cancer that cannot be removed by surgery or has spread. About 895 adults whose cancer has not resp…

This study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…

This trial tests whether personalized nutrition counseling to increase fiber intake can help preserve the diversity of gut microbes in people undergoing treatment for early-stage triple-negative breast cancer. Participants are randomly assigned to receive either coaching from a r…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This study tests the drug trastuzumab deruxtecan in about 500 people with advanced HER2-positive breast cancer, some of whom also have brain metastases. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Participants receive the dru…

This early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…

This study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This Phase 3 trial is testing a new daily pill called camizestrant against standard hormone therapies (like tamoxifen or aromatase inhibitors) in 5,500 people with ER+/HER2- early breast cancer who have a moderate-to-high risk of the cancer returning. Participants take the drug f…

This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…

This trial tests whether giving the immunotherapy drug durvalumab before surgery can help women with early, small triple negative breast cancer. Participants receive two infusions of durvalumab, then either proceed to surgery or, if needed, additional standard therapy. The study …

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This study tests whether combining the immunotherapy drug durvalumab with other cancer treatments (with or without chemotherapy) can help control metastatic triple negative breast cancer in people who have not had prior treatment for advanced disease. About 243 women with advance…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other anti-cancer medicines in people with metastatic HER2-low breast cancer. The goal is to find safe doses and see if the combination can shrink tumors or slow the cancer's growth. About 138 adults with…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This phase 3 trial is testing whether adding an experimental immunotherapy drug called PM8002 to standard chemotherapy (nab-paclitaxel) can help people with advanced triple-negative breast cancer live longer without their disease worsening. The study enrolls women aged 18 to 70 w…

This study follows patients with advanced solid tumors who are already benefiting from the cancer drug spartalizumab (PDR001). The goal is to continue monitoring safety and side effects while allowing patients to keep receiving the treatment. About 120 participants are enrolled f…

This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…

This study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…

This phase 2 trial is testing whether adding the immunotherapy drug cemiplimab (Libtayo) to standard chemotherapy can eliminate more cancer before surgery in people with high-risk or locally advanced breast cancer. The study enrolls 36 participants with either hormone receptor-po…

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with th…

This study offers continued treatment with atezolizumab (Tecentriq) to about 1,000 cancer patients who were already benefiting from it in earlier Roche-sponsored trials. Participants may also receive other drugs like bevacizumab or alectinib. The main goal is to provide ongoing a…

This phase II trial is testing whether a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and fulvestrant (a hormone blocker)—can slow or stop the growth of a specific type of advanced breast cancer. The study enrolls people with ER-positiv…

This phase 3 trial is comparing an experimental drug, BL-M07D1, against the approved therapy T-DM1 in people with advanced HER2-positive breast cancer that has not responded to previous treatments. The study aims to see whether BL-M07D1 can delay cancer progression better than T-…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This Phase 3 trial tests whether adding tucatinib (a targeted pill) to standard therapy (trastuzumab and pertuzumab) can delay cancer growth in people with advanced HER2+ breast cancer. About 654 participants with inoperable or metastatic disease will receive either tucatinib or …

This trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…

This phase 3 trial is testing an experimental oral drug called imlunestrant, alone or combined with abemaciclib, against standard hormone therapies for people with ER+/HER2- advanced or metastatic breast cancer that has worsened after prior hormone treatment. The study aims to se…

This phase 3 trial tests whether a combination of the targeted drug abemaciclib plus hormone therapy works as well as standard chemotherapy for women with ER+ HER2- breast cancer that has spread to the liver, lungs, or other organs. About 180 participants will be randomly assigne…

This study tests a drug called sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has worsened after chemotherapy. The goal is to see how well the drug shrinks tumors and to find biological markers that predict response. Participants recei…

This study tests different levels of a telephone-based weight loss program for cancer survivors who are overweight or obese. All participants start with a core program including written materials, a smartphone app, and optional coaching. Those who lose at least 2% of their weight…

This phase 2 trial tests whether adding immune-boosting drugs (avelumab and utomilumab) to standard chemotherapy and targeted therapy can help people with HER2-positive metastatic breast cancer whose disease has worsened after prior treatments. Participants are randomly assigned …

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…

This study tests the safety of specially prepared T cells that target a protein called mesothelin, found on some breast cancer cells. The cells are collected from the patient's blood, modified in a lab, and then given back along with chemotherapy and another drug. The trial enrol…

This study tests whether analyzing the genetic makeup of a patient's triple-negative breast cancer tumor can help doctors choose the most effective treatment. Patients with newly diagnosed, early-stage triple-negative breast cancer receive either standard chemotherapy or a person…

This study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…

This phase 3 trial tests whether switching to a new oral drug (AZD9833) plus a CDK4/6 inhibitor can delay cancer progression better than staying on standard aromatase inhibitor therapy in people with HR+/HER2- metastatic breast cancer who have an ESR1 mutation. About 315 particip…

This phase II study is testing a combination of three drugs—lenvatinib, pembrolizumab, and letrozole—in people with advanced hormone receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy. The goal is to see if this combination can …

This study tests whether the drug olaparib can help prevent breast cancer from returning in people with inherited BRCA1 or BRCA2 mutations who have already completed surgery and chemotherapy. About 1,800 participants with high-risk, HER2-negative breast cancer will receive either…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This study tests a three-part approach for people with breast cancer that has spread to the brain. First, they receive focused radiation (stereotactic radiosurgery) along with a drug called olaparib, which may make cancer cells more sensitive to radiation. After that, they get an…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This study offers continued treatment with the cancer drug osimertinib to patients who have already benefited from it in a previous trial. The goal is to keep providing the drug while monitoring safety and side effects. About 37 adults with cancer who are still doing well on the …

This trial investigates whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy and HER2-targeted drugs can destroy more cancer before surgery in people with HER2-positive breast cancer. Participants receive one of three treatment combinations befo…

This study is for people with a high-risk type of breast cancer (ER+/HER2-) who have finished initial treatment but still face a chance of the cancer coming back. Researchers will use a simple blood test to look for tiny bits of tumor DNA. If found, participants will be randomly …

This early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…

This pilot study tests whether a resistance training program using weighted sled pushes and pulls can help cancer patients improve muscle mass and reduce body fat. Thirty adults aged 20-89 with a cancer diagnosis will participate in monitored exercise sessions over six months. Re…

This study tests whether a daily pill (Z-endoxifen) plus a monthly shot (goserelin) can slow or stop estrogen-driven breast cancer growth in premenopausal women. About 87 participants will take the drugs for up to 24 weeks before surgery. The main goal is to see if the treatment …

This study tests a new drug called WJ47156, alone or combined with other anti-cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of tumor shrink…

This clinical trial is testing whether combining two drugs, palbociclib and bicalutamide, is safe and effective for people with a specific type of metastatic breast cancer that is triple-negative and androgen receptor positive. The study involves women whose cancer has spread and…

This phase 3 trial compares a new drug combination (KN026 plus HB1801, with or without carboplatin) against the standard treatment (trastuzumab, pertuzumab, and docetaxel, with or without carboplatin) in people with early or locally advanced HER2-positive breast cancer. The goal …

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This study tests a combination of two drugs, capivasertib and fulvestrant, in 101 people with a specific type of advanced breast cancer (HR+/HER2-) that has stopped responding to hormone therapy and a CDK4/6 inhibitor. The goal is to see how long it takes before the next cancer t…

This early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This phase 3 trial compares a new drug, SHR-A1811, to the standard treatment T-DM1 in women with HER2-positive breast cancer who still have cancer cells after initial therapy. The goal is to see if SHR-A1811 can better prevent the cancer from coming back. Participants receive eit…

This phase 2 trial tests whether a vaccine made from a protein found on many triple-negative breast cancer cells can help prevent the cancer from coming back. Participants receive the vaccine along with an immune booster and a low dose of chemotherapy. The study includes women wi…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This study tests whether adding the drug tucatinib to standard therapy (trastuzumab/pertuzumab or T-DM1) can prevent new or worsening brain metastases in people with advanced HER2+ breast cancer. About 48 participants who have stable disease elsewhere but a new brain tumor will r…

This study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-phase study tests whether adding the drug niraparib to standard radiation therapy after surgery can help prevent triple negative breast cancer from coming back. Niraparib is a PARP inhibitor that blocks cancer cells from repairing their DNA. The study includes 21 adult…

This study tests whether combining two drugs (niraparib and dostarlimab) with radiation therapy is safe and effective for people with metastatic triple-negative breast cancer that has not responded to immunotherapy or is PD-L1 negative. About 32 adults with this aggressive cancer…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests whether adding the experimental drug inavolisib to two standard treatments (palbociclib and fulvestrant) can slow cancer growth in people with a specific genetic mutation (PIK3CA) in hormone receptor-positive, HER2-negative advanced breast cancer. About 325 parti…

This study tested whether adding the drug palbociclib for two years to standard hormone therapy (taken for at least five years) helps prevent breast cancer from coming back in people with early-stage HR+/HER2- breast cancer. About 5,800 participants with stage II or III cancer to…

This phase 2 trial tests whether adding an oral targeted drug called anlotinib to standard chemotherapy can better clear cancer from the breast and lymph nodes before surgery in people with early-stage HER2-negative breast cancer. The study enrolled 31 high-risk patients. The mai…

This Phase 3 study tests whether adding the targeted drug alpelisib to standard maintenance therapy (trastuzumab and pertuzumab) can help people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation) live longer without their cancer growing…

This study tests a drug called elacestrant combined with other medicines in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find safe doses and see if these combinations can slow down cancer growth. About 435 adults with metastatic breast cancer wi…

This study tested whether a higher dose (500 mg) of the drug fulvestrant works better than the standard dose (250 mg) in postmenopausal women with a certain type of advanced breast cancer that had worsened after previous hormone therapy. The trial involved 736 participants and me…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This phase III trial tests whether personalized therapy can improve survival for people with high-risk BRCA1-like breast cancer. Participants receive either standard chemotherapy or a more intense regimen with stem cell rescue. The study aims to find a better way to treat this ag…

This study tests the drug letrozole in postmenopausal women with early-stage ER+ breast cancer. Participants take letrozole for 4 to 24 weeks before surgery to see how the tumor changes and to check if they take the medication as prescribed. The goal is to improve treatment for t…

This phase 2 trial tests whether adding alpelisib to continued fulvestrant can help people with advanced, hormone-receptor-positive, HER2-negative breast cancer that has a PIK3CA mutation. Participants have already seen their cancer progress while on fulvestrant. The study aims t…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This study looks at whether adding surgery or radiation to a standard drug combination (palbociclib plus letrozole) can help people with newly diagnosed stage IV ER+/HER2- breast cancer live longer. About 200 women with cancer that has spread beyond the breast will receive the dr…

This study tests a new drug (PF-07220060) plus letrozole against standard treatments for people with HR-positive, HER2-negative advanced or metastatic breast cancer who haven't had prior therapy for advanced disease. About 1,035 adults will be randomly assigned to either the new …

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can completely eliminate tumors in people with localized triple-negative breast cancer. About 51 women with early-stage, untreated disease will receive the combination, then…

This study tests whether adding a non-invasive heat therapy called modulated electro-hyperthermia (mEHT) to standard chemotherapy can shrink tumors more effectively in women with HER2-negative breast cancer. About 71 participants with stage II-III disease will receive chemo with …

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study tests if a combination of ribociclib (a targeted pill) and hormone therapy works better than standard chemotherapy for women with a common type of early breast cancer (HR+/HER2-). About 1,684 women with intermediate-risk disease are taking part. The goal is to see whic…

This study tests whether adding the drug ipatasertib to standard chemotherapy and immunotherapy (atezolizumab) can improve outcomes for women with high-risk triple-negative breast cancer before surgery. About 146 women with newly diagnosed, non-metastatic tumors that are at least…

This Phase 2 trial tests the drug elacestrant in 61 people with estrogen receptor-positive, HER2-negative metastatic breast cancer who have not previously used CDK4/6 inhibitors. Participants take a daily pill for about 6 months. The study aims to see if the drug can delay cancer…

This phase 3 trial compares a new drug called A166 to the standard drug T-DM1 in about 365 people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. Participants must have already been treated with trastuzumab and a taxane…

This was a phase II trial testing a combination of three drugs—zimberelimab, domvanalimab, and sacituzumab govitecan—as a first treatment for people with advanced triple-negative breast cancer that is PD-L1 positive. The study aimed to see how well the drugs shrank tumors and how…

This early-stage trial tests two drugs, alpelisib and sacituzumab govitecan, together in people with advanced HER2-negative breast cancer that has spread or come back. The main goal is to find the safest dose and check for side effects. About 18 adults are taking part in this stu…

This phase 3 trial tests whether adding capivasertib to standard fulvestrant therapy can slow cancer growth in people with advanced HR+/HER2- breast cancer. About 818 participants whose cancer worsened after hormone therapy will receive either the combination or a placebo plus fu…

This phase 2 trial tests whether the number of immune cells in and around a triple-negative breast cancer tumor can help doctors personalize chemotherapy and immunotherapy. About 139 women with early-stage triple-negative breast cancer will receive standard chemotherapy drugs plu…

This phase 2 trial is testing whether a combination of targeted cancer drugs (trastuzumab, pertuzumab, and T-DM1) can effectively treat HER2-positive early breast cancer without traditional chemotherapy. About 393 patients will receive these drugs as a subcutaneous injection, wit…

This Phase III trial is testing whether women and men with early-stage, low-risk HER2-positive breast cancer can safely skip radiation after breast-conserving surgery if they continue HER2-targeted therapy. About 1,300 participants are randomly assigned to receive either standard…

This phase 2 trial tests a two-step treatment for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. First, patients receive a strong drug called trastuzumab deruxtecan (T-DXd) to shrink the cancer. Then, they switch to a maintenance therapy …

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This phase 3 study tests whether adding the targeted drug abemaciclib to standard hormone therapy helps prevent breast cancer from returning in people with high-risk, early-stage, hormone receptor-positive, HER2-negative breast cancer that has spread to lymph nodes. Over 5,600 pa…

This Phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) can prevent breast cancer from returning in patients with HER2-negative breast cancer who still have cancer after initial chemotherapy. About 1,332 participants will receive either the new drug or standard…

This Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…

This phase 2 trial tests whether adding the immunotherapy drug durvalumab to two standard targeted drugs (trastuzumab and pertuzumab) can shrink tumors more effectively in people with HER2-enriched breast cancer. The study involves 51 participants and measures how many have no or…

This early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…

This phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus…

This study aimed to test the safety and effectiveness of combining the drug ribociclib with hormone therapy and radiation for women aged 70 and older with a certain type of breast cancer. The goal was to control the disease without surgery. However, the study was withdrawn before…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This study tests whether adding the experimental drug ipatasertib to standard hormone therapy and targeted drugs can help people with a certain type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. It includes 57 participants whose cancer did not re…

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…

This phase 3 trial tests whether adding the experimental drug ipatasertib to standard hormone therapy (fulvestrant) can slow the growth of advanced ER-positive, HER2-negative breast cancer. The study enrolls 250 postmenopausal women whose cancer worsened after initial treatment w…

This phase 3 study compares a targeted drug called sacituzumab govitecan against standard chemotherapy in about 623 people with advanced triple-negative breast cancer that does not express PD-L1 (a protein that makes immunotherapy work). Participants either have not received prio…

This phase 3 trial tests a new oral hormone therapy called imlunestrant against standard hormone therapies (like tamoxifen or aromatase inhibitors) in 8,000 people with ER+/HER2- early breast cancer who have already had 2-5 years of hormone therapy and are at higher risk of recur…

This Phase 2 trial is testing whether a combination of two targeted drugs (trastuzumab and pertuzumab) given as a single shot under the skin, along with standard hormone therapy, can prevent cancer from returning after surgery in people with early-stage, hormone receptor-positive…

This study compares the brand-name drug Ibrance (palbociclib) with a local generic version in 100 Iraqi women with stage IV hormone receptor-positive, HER2-negative breast cancer. The goal is to see if the generic works just as well and is as safe as the brand. Patients take the …

This study compares an oral version of the chemotherapy drug paclitaxel (Liporaxel) with the standard IV version (Taxol) in 549 people with recurrent or metastatic HER2-negative breast cancer. The goal is to see if the pill works as well or better at controlling the disease and i…

This phase 2 trial is testing whether adding the targeted drug dalpiciclib to standard hormone therapy (letrozole) before surgery can improve outcomes for women with HR+/HER2- early-stage breast cancer. The study enrolls 100 women aged 18-70 whose tumors have a high genetic risk …

This Phase 3 trial is testing an experimental oral drug called ARV-471 against a standard injectable drug, fulvestrant, in people with a common type of advanced breast cancer (ER+/HER2-). The study includes 624 participants whose cancer has worsened after prior hormone-based trea…

This study tests whether combining hormone therapy, a targeted drug (palbociclib), and an immunotherapy (avelumab) can shrink early-stage, hormone-positive breast tumors before surgery. About 33 women with stage II-III breast cancer will receive the treatment for about 4 months, …

This phase 2 trial tests whether adding ribociclib to letrozole before surgery helps more women with ER-positive, HER2-negative early breast cancer achieve a low-risk score (PEPI 0) compared to letrozole alone. About 121 postmenopausal women with stage II or III breast cancer wil…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) for people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. About 14 participants will receiv…

This early-phase trial tests whether adding a single, focused dose of radiation before surgery can make the immunotherapy drug pembrolizumab work better in people with early-stage breast cancer. About 27 participants will receive both treatments, then have surgery to see if the t…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This phase II trial is testing a less intense chemotherapy regimen for people with early-stage HER2-positive breast cancer. The experimental treatment combines paclitaxel with two targeted drugs (trastuzumab and pertuzumab), skipping the harsher anthracycline drugs. Researchers w…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This trial is testing whether giving a small dose of targeted radiation to a part of the breast tumor before standard chemotherapy can help the immune system fight the cancer more effectively. The study includes 40 people with high-risk or locally advanced breast cancer. After ra…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This phase 3 trial tests whether adding the drug palbociclib to standard anti-HER2 therapy and hormone therapy can help people with HR+/HER2+ metastatic breast cancer live longer without their cancer getting worse. About 518 participants who have already received initial treatmen…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was designed for adults with metastatic disease. However, the trial was withdrawn …

This Phase 3 trial tests a new experimental drug, vepdegestrant, combined with palbociclib against the standard treatment (letrozole plus palbociclib) for people with advanced ER+/HER2- breast cancer that has not been treated before. The study aims to see if the new combination w…

This Phase 3 trial is testing a new drug called gedatolisib combined with fulvestrant, with or without palbociclib, in about 700 people with advanced HR+/HER2- breast cancer that has worsened after prior treatment. The goal is to see if this combination can slow cancer growth bet…

This phase 3 trial tested whether adding the drug everolimus to standard hormone therapy helps prevent breast cancer from returning in nearly 2,000 patients with high-risk, hormone receptor-positive, HER2-negative breast cancer. Participants received either hormone therapy plus e…

This study tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) plus chemotherapy in 81 women with triple negative breast cancer. It includes two groups: those with early-stage cancer and those with advanced (metastatic) cancer. The goal is to see if the …

This phase 3 trial tests whether adding the drug abemaciclib to standard hormone therapies (anastrozole, letrozole, or fulvestrant) can help slow cancer growth in postmenopausal women with a common type of advanced breast cancer (HR+, HER2-). About 463 women participated, and the…

This phase 2 study tests the drug abemaciclib, either alone or with tamoxifen, in 234 women with a specific type of advanced breast cancer (HR+, HER2-). The goal is to see if these treatments can slow cancer growth in patients whose disease has progressed after prior therapies. P…

This phase 3 trial tests whether adding abemaciclib to standard hormone therapy (anastrozole or letrozole) can slow cancer growth in postmenopausal women with HR+ HER2- breast cancer that has spread or returned. About 493 women participated, receiving either the drug combination …

This study tests whether adding abemaciclib to fulvestrant can slow or stop the growth of a common type of advanced breast cancer (HR+, HER2-) that has worsened after initial treatment. About 368 participants will receive either the drug combo or a placebo plus fulvestrant. The g…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This phase 3 study tests a 3-month injection (TOL2506) to temporarily stop ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The goal is to see if it works well with hormone therapy (tamoxifen or aromatase inhibitors) to control the cancer. About 250 …

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…

This study follows 170 women with early-stage HER2+ breast cancer who are receiving the biosimilar drug Zedora after surgery. Researchers want to see how well it prevents the cancer from coming back and how safe it is in real-world settings, where patients may have other health i…

This study aimed to see if the drug capivasertib could clear cancer DNA from the blood of women with ER-positive breast cancer who had finished initial treatment. The goal was to prevent the cancer from coming back or spreading. However, the study was withdrawn before any partici…

This Phase 2 trial is testing whether adding the drug ribociclib (Kisqali) to standard hormone therapy can improve outcomes for people with early-stage ER-positive breast cancer. The study involves 120 participants and focuses on clearing cancer DNA from the blood. The goal is to…

This phase 3 trial tests whether adding capivasertib (a targeted drug) to standard chemotherapy (paclitaxel) helps people with advanced triple-negative breast cancer live longer. About 923 participants receive either the combination or a placebo plus chemotherapy. The study is no…

This study is testing the safety and effectiveness of combining trastuzumab deruxtecan (T-DXd) with other cancer drugs for people with HER2-positive metastatic breast cancer. About 245 participants will receive different drug combinations to find the best doses and see if the tum…

This study tests a new combination of two drugs (Debio 0123 and sacituzumab govitecan) in people with advanced breast cancer that has not responded to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 76 adults with triple-n…

This early-phase study tests a new drug called GH2616 in about 126 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein (KIF18A) that helps cancer cells divide, which may slow or stop tumor growth. The main goals are …

This study tests whether adding a targeted drug called AZD5363 to the standard hormone therapy fulvestrant can slow the growth of advanced estrogen-receptor-positive (ER+) breast cancer. It involves 149 postmenopausal women whose cancer has worsened despite prior treatment with a…

This study looks at whether adding pegfilgrastim (a drug that increases white blood cells) to standard chemotherapy and trastuzumab can help the immune system better attack HER2-positive breast cancer before surgery. About 90 women with early-stage, operable breast cancer will ta…

This phase 2 trial tests whether a newer drug, margetuximab, combined with chemotherapy, works better than the standard trastuzumab combination for HER2-positive breast cancer before surgery. The study includes 174 people with stage II or III disease who have a specific genetic v…

This phase 2 trial is testing whether adding the drug tucatinib to standard treatments (pertuzumab and trastuzumab) can help people with HER2-positive metastatic breast cancer whose cancer has progressed in the brain after local therapy. About 53 participants will receive tucatin…

This phase 3 trial studies whether adding the drug abemaciclib (Verzenios) to standard hormone therapy helps prevent breast cancer from coming back in 1,260 women with high-risk, HR+/HER2- early breast cancer. Participants have already completed initial treatments like surgery or…

This phase 3 study tested whether adding the drug abemaciclib to standard hormone therapy (fulvestrant) helps women with a common type of advanced breast cancer (HR+, HER2-) live longer without their cancer growing. About 669 women took part, receiving either the combination or f…

This study tests a new oral drug, camizestrant, combined with palbociclib against the standard anastrozole plus palbociclib in people with ER-positive, HER2-negative advanced breast cancer who haven't had prior treatment for advanced disease. About 1,370 participants will be foll…

This study was designed to test whether a biosimilar version of pertuzumab (EG1206A) works as well as the original drug (Perjeta) in people with HER2-positive, hormone receptor-negative early breast cancer. Participants would have received either the biosimilar or the original dr…

This phase 3 study tests whether the drug sacituzumab govitecan (Trodelvy) can help people with a common type of advanced breast cancer (HR+/HER2-) live longer without their cancer growing. About 654 participants will receive either the new drug or one of three standard chemother…

This phase 2 trial tests whether a combination of two drugs, ribociclib and letrozole, can replace standard chemotherapy for postmenopausal women with a common type of breast cancer (hormone receptor positive, HER2 negative). The study involves 100 participants who will receive e…

This phase 2 trial is testing whether doctors can safely reduce the amount of chemotherapy given to people with HER2-positive breast cancer by using imaging scans to guide treatment. The study involves 462 participants with stage II or III disease who receive a combination of dru…

This phase 3 trial tests whether combining sacituzumab govitecan (Trodelvy) with pembrolizumab (Keytruda) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that has a protein called PD-L1. About 443 participants who …

This phase 2 trial is testing whether adding the targeted drug pyrotinib to standard chemotherapy and trastuzumab before surgery can eliminate more cancer in women with HER2-positive early breast cancer. About 53 participants will receive the combination, and the main goal is to …

This phase 2 trial is testing a combination of three drugs—atezolizumab, trastuzumab, and vinorelbine—in people with HER2-positive advanced or metastatic breast cancer that has already been treated with trastuzumab and other anti-HER2 therapies. The study focuses on patients whos…

This Phase 3 trial tests whether a combination of targeted drugs (trastuzumab, alpelisib, and possibly fulvestrant) can work better than standard chemotherapy for people with a specific genetic mutation (PIK3CA) in HER2+ advanced breast cancer. The study enrolled 27 participants …

This study was designed to test a combination of two drugs, Ezabenlimab and BI907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the treatment could control the disease for at least 24 weeks. However, the trial was wi…

This study is testing whether regular MRI scans of the brain can find cancer that has spread from the breast to the brain, even before symptoms appear. It involves 214 people with metastatic or inflammatory breast cancer. The goal is to see if early detection through screening im…

This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…

Researchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…

This early-stage trial is testing whether a new radioactive imaging agent, called [99mTc]Tc-DARPinEc1-G3C, can safely and effectively visualize breast cancer tumors using SPECT/CT imaging. The study involves about 10 people with primary triple-negative or luminal breast cancer. P…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This phase I trial tests an experimental imaging agent called 64Cu-DOTA-pembrolizumab, which is designed to attach to PD1, a protein on immune cells that often cluster around tumors. By injecting this agent and then performing a PET scan, researchers hope to see where these immun…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This trial is testing an experimental imaging agent called [68Ga]Ga-ELI411, which is designed to bind to a protein (FAP) found in many solid tumors. The study will involve 18 adults with confirmed solid tumors who are already scheduled for a standard FDG-PET scan. Participants wi…

This study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …

This study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…

This study tests whether a simple 30-second ECG using a handheld device can find undiagnosed atrial fibrillation (an irregular heartbeat) in people aged 65 and older with cancer. About 500 participants will be randomly assigned to either get the quick screening or usual care. The…

This study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…

This study tests whether empagliflozin, a drug used for diabetes, can prevent heart damage in cancer patients receiving strong chemotherapy (anthracyclines). About 220 adults with cancer but no prior heart failure will take either the drug or a placebo daily for 12 months. The go…

This study tests a type of talk therapy called dignity therapy, adapted for sexual and gender minority (LGBTQ+) cancer patients. A trained researcher will interview participants about their lives and create a poem or legacy document they can share with loved ones. The goal is to …

Depression is common among cancer survivors, but many don't get help. This pilot study tests a text-based referral platform that sends tailored messages and a video to encourage survivors to take up a mental health referral. The study will enroll 60 cancer survivors with depressi…

This study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…

This pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…

This study tests a program called ASCENT that helps cancer survivors manage pain using an educational guide and coaching from community health workers and pain care managers. The goal is to improve pain control and lower the risk of opioid misuse. About 660 adults with cancer-rel…

This study tests whether inhaling lavender aromatherapy oil can reduce anxiety and pain for cancer patients undergoing a bone marrow biopsy. About 45 adults with cancer will be asked to use the oil during the procedure. The goal is to see if this simple, drug-free approach is som…

This study tests a communication coaching program for adolescent and young adult cancer survivors (ages 18-35) who have finished treatment at least a year ago. Participants complete online sessions and AI coaching to improve how they talk with peers. The goal is to see if the pro…

This trial tests whether six weeks of upper cervical chiropractic care can help adults who have finished cancer treatment but still struggle with chronic fatigue. The study focuses on whether such a trial is practical, looking at recruitment, adherence, and acceptability. Partici…

This study tests a program called TIPPI-R that teaches children with cancer and their families ways to manage pain and distress during treatment. About 100 children aged 0-18 will either receive the program or standard care. Researchers will compare how well they cope with pain a…

This pilot trial tests whether Acceptance and Commitment Therapy (ACT), a type of talking therapy, can help disease-free cancer survivors manage chronic pain and reduce long-term opioid use. Participants attend six weekly virtual sessions with a psychologist. The study focuses on…

This study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…

This trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…

This study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…

This study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …

This study tests whether adding a trained community health worker (CHW) to standard care can improve quality of life and advance care planning for African American patients with advanced cancer. 160 patients will either receive standard care or standard care plus CHW support. The…

This trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…

This study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …

This study looks at whether starting hormone therapy every other day for one month, then switching to daily, helps women with early breast cancer take their medication as prescribed. About 240 participants will be randomly assigned to either the standard daily dose or the gradual…

This study tests a drug called elinzanetant to see if it can reduce hot flashes in women with hormone-receptor positive breast cancer who are on hormone-blocking therapy. About 474 women will take either the drug or a placebo for 12 weeks, then all will receive the drug for up to…

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This study explores whether a structured survivorship care visit, conducted early in cancer treatment, can help reduce psychological distress and improve quality of life. Adults with any type of cancer who report significant distress will meet with a physician assistant to discus…

This phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…

This study tests whether a financial navigation and counseling program (CostCOM) can help newly diagnosed cancer patients who are struggling with costs or basic needs like food and housing. About 91 patients will either get the program, educational materials, or usual care. The g…

This study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …

This study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study compares a 12-week digital home-based resistance exercise program to a supervised on-site program for cancer survivors who finished treatment up to 5 years ago. The main goal is to see which approach leads to better exercise adherence. Researchers will also measure eff…

This study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…

This study tests whether up to two doses of psilocybin (the active ingredient in magic mushrooms) can safely reduce depression in adults who have both cancer and major depressive disorder. About 56 participants will receive either psilocybin or a placebo in a first session, and t…

This study tests whether a brief behavioral therapy (BBT-CI) or a healthy eating education program (HEAL) works better for reducing insomnia in cancer patients. About 400 adults with stage I-IV cancer who are currently receiving treatment and have sleep problems will take part. T…

This study tests whether a structured exercise program can reduce chemotherapy-induced peripheral neuropathy (CIPN) — nerve damage causing pain, numbness, or tingling. About 133 cancer patients who received certain chemotherapies will either follow an exercise plan or receive sta…

This study tests whether a mobile app called SUPPORT+ can improve quality of life for adults with advanced cancer who are no longer receiving anticancer treatment. Participants use the app to report symptoms weekly, get self-care tips, and receive nurse follow-up if symptoms are …

This pilot study explores whether chiropractic adjustments to the upper neck can reduce chronic fatigue in adults who have finished cancer treatment. About 40 cancer survivors who are currently cancer-free will receive either immediate or delayed chiropractic care for 6 to 12 wee…

This study gives 250 advanced cancer patients $1,000 each month for a year to see if it reduces financial stress and improves quality of life. Participants also complete surveys every three months. The goal is to learn whether extra income can help patients stick to treatments an…

This study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves…

This study looks at two treatments for vaginal dryness in women with estrogen receptor-positive breast cancer who are taking aromatase inhibitors. One group uses a vaginal estrogen ring that releases a low dose of estrogen over 90 days, while the other uses a non-hormonal vaginal…

This study tests whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help cancer patients and survivors with clusters of symptoms like memory problems, fatigue, insomnia, anxiety, and depression. Seventy participants will receive either real electro…

This study looks at whether the anti-nausea drug NEPA (netupitant/palonosetron) can prevent vomiting and nausea in people with advanced HER2-positive or HER2-low breast cancer who are receiving the drug T-DXd. It will follow 100 participants across multiple hospitals to see how w…

This study tests whether a mobile health program can help adolescents and young adults (ages 15-39) who finished cancer treatment become more physically active. Participants get a personalized activity plan, a fitness tracker, access to an online survivor community, and motivatio…

This study tests whether a phone app called OnKO-Tips&Tricks can improve the quality of life for adolescents and young adults (ages 15-25) recently diagnosed with cancer. The app helps with daily check-ins, education, and connecting with a nurse coordinator. Researchers will comp…

This study tests whether nature-based therapies can reduce fatigue and improve sleep, mood, and concentration in cancer survivors. 172 participants will be assigned to real forest bathing, a virtual reality forest experience, guided imagery, or a waitlist. Each session lasts 30 m…

This study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This study is testing a 24-week program that combines nutrition counseling, exercise, sleep tips, and stress management for cancer survivors who are overweight. Researchers want to see if the program is practical and helpful for improving sleep quality, reducing stress, and boost…

This study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…

This study will collect blood and tumor tissue from up to 50,000 adults with hereditary or genetic-linked cancers. Researchers will use these samples to create lab-grown tumor models, like mini-tumors, to study how these cancers work and test new treatments. The goal is to better…

Researchers are testing an online decision support tool called Gene PilotLX to see if it helps Latinx cancer patients make informed choices about tumor genomic testing. Tumor genomic testing looks for genetic changes in a tumor that might guide treatment or reveal hereditary risk…

This study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.

This study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …

This study looks at whether certain genetic variations can predict which women with early-stage breast cancer will stop taking anastrozole, a common hormone therapy, because of joint and muscle pain. Researchers will follow about 1,046 postmenopausal women who are prescribed anas…

This study aims to map the genetic makeup of breast and prostate cancers in patients treated through Brazil's public health system. Researchers will analyze tumor and normal DNA from 882 participants to build a national database. The goal is to better understand how genetics and …

This study tests whether an AI tool can accurately summarize serious illness conversations between doctors and cancer patients. Researchers will send these summaries to doctors caring for hospitalized patients with advanced cancer. The goal is to see if the summaries are accurate…

This study looks at whether watching an online genetics video, with or without phone counseling from a genetic counselor, can reduce the stress women feel about their cancer risk. It involves 5,200 women aged 30 or older who have had triple-negative breast cancer and still have a…

This study looks at how children with cancer and their parents handle the emotional challenges of the disease. Instead of focusing only on negative effects like posttraumatic stress, researchers also explore positive changes, such as personal growth. The study compares these fami…

This study explores whether a special MRI scan can serve as a non-invasive biomarker to predict how early breast cancer responds to immunotherapy. Researchers will compare MRI features with tissue and blood samples from about 10 patients with hormone receptor-negative, HER2-negat…

This trial tests whether a structured, nurse-led symptom screening program can increase the number of cancer survivors who are screened for distress and referred to supportive services. The program includes nurse training and regular feedback, and it will be rolled out across mul…

This study investigates whether early changes on a PET scan can predict which patients with HER2-positive breast cancer will have a complete response to a combination of trastuzumab and pertuzumab given before surgery. Participants receive the two drugs and undergo PET scans at t…

This study looks at whether a new scoring system, called the DIEP-MDS, can help predict the risk of blood flow problems and flap failure after DIEP flap breast reconstruction. The score is based on CT scans of the abdomen, measuring features of the blood vessels used in the surge…

This study aims to find out how often cancer patients treated with opioids for pain are at risk of misusing these medications. Researchers will use two screening questionnaires to assess misuse risk in 200 adult outpatients receiving opioids for cancer-related pain. The findings …

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study is investigating whether genetic changes in tumor tissue and blood can predict how well people with hormone receptor-positive metastatic breast cancer respond to a combination of endocrine therapy and palbociclib. Researchers will collect tumor samples and blood from p…

This study is for women with breast cancer who are receiving a treatment that greatly lowers estrogen levels. Researchers want to see if this treatment changes how the heart works. They will use heart scans to measure blood flow in 90 women over two years. The goal is to learn mo…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…

This study is looking at how triple-negative breast cancer evolves during chemotherapy. Researchers will take biopsies from the tumor before, during, and after treatment to see if the diversity of cancer cells affects how well the tumor responds. The goal is to understand why som…

This study is testing whether a chatbot can help parents of children with cancer learn about genetic risks and decide whether to get tested themselves. The chatbot provides education and support as an alternative to speaking with a genetic counselor. The goal is to make it easier…

This study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…

This large observational study looks at whether getting an mRNA COVID-19 vaccine shortly before or after starting immune checkpoint inhibitor therapy is linked to longer survival in adults with cancer. Using data from nearly 100,000 patients in France, researchers are comparing t…

This study looks at how community cancer clinics screen for health-related social needs, like help with housing, food, or transportation. Researchers will work with 144 clinic staff to understand what helps or hinders screening. The goal is to create custom plans to make screenin…

This study combines MRI scans with detailed genetic and molecular analysis (multiomics) to improve how luminal breast cancer is classified and treated. Researchers aim to develop models that predict treatment resistance, recurrence, and spread, helping doctors choose the most eff…

This study looks at how the drug ribociclib is actually used in everyday medical practice for people with a common type of early breast cancer (HR+/HER2-). Researchers will analyze medical records from thousands of patients to see who gets the drug, how long they take it, and wha…

This study explores whether genetic testing from a simple saliva sample can improve risk assessment for breast cancer in women who need a breast biopsy. Researchers will analyze DNA from saliva to calculate a polygenic risk score and compare it with biopsy results and medical rec…

This study is developing an artificial intelligence model that can analyze frozen-section pathology images—tissue samples examined during surgery. The goal is to help pathologists quickly and accurately diagnose cancer while the patient is still in the operating room. Researchers…

This study looks back at medical records of 300 people with metastatic luminal A or luminal B breast cancer who were treated with CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib). The goal is to see how long patients lived without their cancer getting worse, and whethe…

This study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…

This study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…

This trial tests whether a pharmacist-led educational program helps cancer patients on high-risk chemotherapy better understand and follow neutropenic precautions—steps to prevent serious infections when white blood cell counts are low. About 300 adults with various cancers will …

This study creates a registry of cancer patients who have had their tumor genes analyzed. Participants fill out a 10-minute survey about their exercise habits before and after diagnosis. Researchers will look for connections between physical activity and genetic changes in tumors…

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…

This study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at how the activity of an enzyme called DPD influences how well the chemotherapy drug capecitabine works in women with metastatic breast cancer. Researchers will measure DPD activity before treatment and track tumor response over 24 months. The goal is to see if …

This study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …

This study involves 15 postmenopausal women with metastatic ER+ breast cancer. Researchers are testing a special PET scan that uses a radioactive tracer to see estrogen receptors on tumors. The goal is to find the best way to measure these receptors, which could help doctors know…

This study tests a web-based tool called REFLECT, designed to help adolescent and young adult cancer patients learn about fertility and genetic risks for future children. Sixteen participants who have had cancer care at Moffitt Cancer Center will use the tool and rate how easy an…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…

This study is for people with HER2-positive metastatic breast cancer who have had a lasting response (complete or partial remission for over 2 years) on anti-HER2 therapy. Researchers will use a personalized blood test called Signatera to look for tiny amounts of cancer DNA. The …

This study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …

This study looks at 625 people in Russia with high-risk early-stage breast cancer that is HER2-negative. Researchers want to find out how many have BRCA1 or BRCA2 gene mutations and what treatments they receive in real-world practice. Participants provide blood and tumor samples …

This study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.

This study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…

This study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…

This study tests whether personalized telehealth coaching can help young adult cancer survivors become more physically active and improve their diet. Researchers are enrolling 374 survivors aged 18-54 who are not very active. Participants receive one-on-one sessions with a clinic…

This study follows over 1,400 patients in Germany and Austria with HR+/HER2- advanced breast cancer who are receiving standard first-line treatment with palbociclib plus hormone therapy. Researchers are collecting real-world data on how long the cancer stays controlled and overal…

This study follows over 1,100 women with early-stage, hormone-sensitive breast cancer who took the EndoPredict® gene test. Researchers want to see if those classified as 'low risk' can safely receive only hormone therapy without chemotherapy. The goal is to confirm that 10-year s…

This study looks at whether training and support can help cancer clinics give special check-ups (called geriatric assessments) to patients aged 65 and older who are starting a new cancer treatment. These check-ups help find and address health issues, support needs, and daily life…

This study compares a new total body PET scanner (Omni TB) with conventional PET in 25 adult cancer patients. The new scanner can image the whole body at once with higher sensitivity, potentially allowing shorter scan times and lower radiation doses. Researchers will assess wheth…

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study follows 329 older patients (65 years and up) with HR+HER2- advanced breast cancer who are taking ribociclib combined with endocrine therapy as their first or second treatment. Researchers are tracking quality of life, treatment effectiveness, and safety in real-world c…

This study looks at whether certain blood cell counts and tumor-infiltrating lymphocytes can help predict if triple negative breast cancer will come back. Researchers will collect blood samples from 90 women after radiation and at the time of any first recurrence. The goal is to …

This study tests whether a wearable skin sensor can tell the difference between mild, moderate, and severe pain in 37 adults with cancer or COPD. Participants wear the device for up to a week and report their pain levels. The goal is to create an algorithm that alerts caregivers …

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study watches how women with a certain type of advanced breast cancer are treated with the drug ribociclib in everyday medical practice in France. It does not give any new treatment but simply collects information on dosing, side effects, and how long the drug works. About 1…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…

This study looks at whether combining genetic tests, regular drug level checks, and careful medication reviews can help doctors prescribe the right drugs and avoid harmful side effects. It involves 450 adults with cancer and children with chronic inflammatory diseases. The goal i…

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study was designed to see if a 14-day course of the drug Anakinra could change the immune environment around early-stage triple-negative or ER-low breast tumors. It was planned for people with small, early-stage tumors who were not scheduled for chemotherapy before surgery. …

This study is testing a new radiation technique that uses real-time MRI scans to target cancer more precisely. About 377 adult cancer patients will receive this treatment and have extra scans and quality-of-life surveys. The goal is to see if this approach improves tumor control …

This study looks at whether it's possible to track memory and thinking changes in adults aged 65 and older who are starting a new type of cancer treatment called immune checkpoint inhibitors. Thirty participants will take simple memory and concentration tests every six weeks for …

This study takes tumor tissue from 50 women with invasive breast cancer and grows mini 3D versions called organoids in the lab. These organoids are used to collect tiny particles called extracellular vesicles, which naturally seek out tumor cells. The goal is to use these particl…

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study looks at a new method for giving the cancer drug vincristine to infants and young children. The goal is to see if this new way of calculating the dose leads to similar drug levels in the blood as the standard method used in older children. About 83 children up to 12 ye…

This study looks at how doctors and nurses in radiation oncology used telehealth instead of in-person visits during the COVID-19 pandemic. Researchers will survey 1,000 healthcare providers at Duke Cancer Center to understand their experiences and challenges. They will also track…

This study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study collects tumor and blood samples from 241 women with HR+/HER2- advanced breast cancer before and after treatment with ribociclib (Kisqali) plus hormone therapy. Researchers will analyze DNA and RNA changes to find markers that predict who responds well and who develops…

This study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…

This study looks at whether measuring certain inflammatory proteins (cytokines) in the blood during radiotherapy can help predict which triple-negative breast cancer patients are likely to have their cancer come back. Researchers will take blood samples from 15 women before and d…

This study looks at how the COVID-19 pandemic changed the number of new cancer cases in Bavaria, Germany. Researchers analyzed data from 438,000 adults diagnosed with cancer between 2018 and 2023 to see if certain regions or cancer types were more affected. The goal is to underst…

This study looks at financial problems (called 'financial toxicity') in young adults aged 18-39 who have finished cancer treatment. Researchers will survey 300 participants to measure money stress during and after therapy, and find out what factors make it worse. The goal is to l…

This study looks at how mind-body therapies—like mindfulness, laughter yoga, and art therapy—affect the quality of life and emotional distress of 150 cancer patients. Participants will fill out questionnaires before and after an 8-week program. The goal is to see if these therapi…

This study uses stem cells made from patients' own cells to understand why some people develop severe heart or lung side effects from certain chemotherapy drugs. Researchers will compare cells from patients who had extreme toxicity to those who did not. The goal is to uncover the…

This trial was designed to test whether adding aspirin to the immunotherapy drug avelumab could help the immune system fight triple-negative breast cancer. Participants would have received either avelumab alone or with aspirin for about 18 days, with biopsies and blood tests to m…

This study follows 376 people with HR+HER2- advanced breast cancer who are taking ribociclib (Risarg) plus endocrine therapy or chemotherapy as part of their routine care in Russia. The goal is to see how long patients stay on treatment before stopping for any reason. Since this …

This study looks at whether simple blood tests can tell if a woman's metastatic breast cancer is stable, so she can skip some routine scans. About 97 women with ER-positive/HER2-negative cancer will give blood samples at each scan visit. The goal is to create a smart algorithm th…

This study looks at whether a set of proteins in the blood can predict if triple-negative breast cancer will come back after treatment. Researchers will follow 90 women and test their blood at several time points. The goal is to find a simple way to identify patients who need clo…

This study looks at whether a genetic test (BRCA1-like) can help doctors choose the best first chemotherapy for people with advanced triple-negative breast cancer. About 304 participants will receive either carboplatin-cyclophosphamide or paclitaxel, with or without the immunothe…

This study is testing an online questionnaire called CHAMP that older adults with cancer can fill out before their doctor's visit. The tool asks about daily function, memory, mood, and support to help doctors tailor cancer treatment. Researchers want to see if the tool is easy to…

This study looks at whether certain inherited gene changes (EGFR mutations) increase the risk of lung cancer, especially in people who never smoked. Researchers collect saliva from cancer patients with a specific tumor mutation (T790M) to find these inherited changes. They also o…

This study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…

This study follows 196 women aged 11-35 who are receiving chemotherapy for cancer. Researchers measure hormone levels and ovarian follicles before, during, and after treatment to see how the ovaries are affected. The goal is to better understand the risk of early menopause and fe…

This study looks at how well cancer patients respond to common vaccines like flu, COVID-19, and shingles. Researchers will measure antibody levels before and after vaccination in 250 adults with cancer. The goal is to understand immune responses in this group, not to test a new t…

This study looks at whether taking hormone therapy for 3 months before breast cancer surgery helps women aged 65 and older decide if they want radiation after surgery. The goal is to see if the experience of taking the pills changes their preference. The study does not test a new…

This study looks at whether a blood test (liquid biopsy) can find cancer mutations as well as the standard tissue biopsy. Researchers will compare the two methods in 1,500 advanced cancer patients to see if the blood test helps doctors choose better treatments and saves money. Th…

This study was designed to see if a new monitoring algorithm could detect early signs of ovarian damage in women and girls who had cancer treatment. Researchers planned to compare a group using the new algorithm with a group that received standard care. However, the study was wit…

This study is checking if two substances in the blood, called IGF-1 and IGF-1Ec, are linked to how much cancer is in the body. Researchers will measure these levels in 100 adults with solid tumors and compare them to tumor size, stage, and spread. The goal is to see if these mark…